Sex differences in the aging pattern of renin–angiotensin system serum peptidases by Fernández Atucha, Ainhoa et al.
RESEARCH Open Access
Sex differences in the aging pattern of
renin–angiotensin system serum peptidases
A. Fernández-Atucha1, A. Izagirre2, A. B. Fraile-Bermúdez1, M. Kortajarena1, G. Larrinaga1, P. Martinez-Lage2,
E Echevarría3,4 and J. Gil3,4*
Abstract
Background: Serum peptidases, such as angiotensin-converting enzyme (ACE), angiotensin-converting enzyme-2
(ACE2), neutral endopeptidase (NEP), aminopeptidase N (APN), and aminopeptidase A (APA), are important elements of
the renin–angiotensin system (RAS). Dysregulation of these enzymes has been associated with hypertension and
cardiovascular risk. In the present study, serum activities of RAS peptidases were analyzed to evaluate the existence of
sexual differences, with a possible different pattern in pre- and post-andropausal/post-menopausal participants.
Methods: One hundred and eighteen healthy men and women between 41 and 70 years of age (58 women and 60
men) were recruited to participate in the study. Serum RAS-regulating enzymes were measured by spectrofluorimetry.
Enzymatic activity was recorded as units of enzyme per milliliter of serum (U/mL).
Results: Significantly lower serum APA activity was observed in men with respect to women; no sex differences were
detected for ACE, ACE2, NEP, or APN. Significantly lower APA and ACE serum activity were observed in older men
compared to older women. In contrast, younger (<55 years) men had significantly higher values of NEP serum activity
than younger women. Significantly lower ACE serum activity was detected in older men compared to younger men.
In women, significantly higher ACE2 serum activity was observed in older women compared to younger women.
Conclusions: These results suggest a differential effect of aging on the activity of RAS enzymes in men and women,
especially with respect to the breakpoint of andropausia/menopausia, on the critical serum enzymatic activities of the
RAS, which could correlate with sexual differences in cardiovascular risk.
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Background
The renin–angiotensin system (RAS) has been classically
described as a circulating hormone system that regulates
hydroelectrolytic balance and cardiovascular function [1].
The better-known bioactive peptide of RAS, angiotensin
II, is produced by the action of angiotensin-converting
enzyme (ACE) and acts through AT1 receptors [1]. The
use of ACE inhibitors and AT1 receptor blockers is the
universally recognized first-line strategy in the treatment
of hypertension and cardiovascular disease [2].
Over the past 25 years, the classic understanding of RAS
has undergone an extensive revision [3, 4]. The activities of
different angiotensin-converting peptidases have been
shown to produce several angiotensins that counterbalance
the action of Ang II [1]. Further, several organs, tissues, and
cells express all the components of RAS [5]. These local and
intracellular RAS can regulate long-term biologic processes
such as cell growth, proliferation, and tissue repair [1, 4, 5].
The newly expanded view of RAS describes endocrine,
paracrine, autocrine, and intracrine functions and demon-
strates that this peptidergic system regulates more diverse
physiological phenomena than previously described [1, 4].
Moreover, the imbalance of RAS components has been as-
sociated with several chronic pathologies that go beyond
cardiovascular and renal diseases [6], including proliferative
(such as cancer) [7, 8] and degenerative disorders of the cen-
tral nervous system (such as Alzheimer’s disease) [9, 10].
These diseases are primarily responsible for morbidity and
mortality of adults in Western countries [11–13]. For this
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reason, there is great utility for RAS-modulating drugs and
application of RAS components as diagnostic/prognostic
biomarkers of chronic diseases [4, 7, 9, 14, 15].
Experimental evidence suggests an important influence of
gonadal hormones on RAS, which could explain, in part, sex
differences in arterial pressure and in the onset of cardiovas-
cular diseases [3, 16]. Studies in animal models have shown
that the expression of angiotensin-converting enzymes is reg-
ulated by estrogens and testosterone in several tissues [16].
These peptidases can be secreted to the extracellular space
from several different tissues [17], and gender differences are
reflected in body fluids [10]. Studies performed in children
and young adults have described basal activity of ACE, as
well as the maximum ACE inhibition after enalapril treat-
ment, and found that they are significantly lower in women
than in men, suggesting that estrogens and androgens could
affect serum soluble ACE activity and lead to sexual differ-
ences in blood pressure [18]. Therefore, sex differences
should be considered in the study of RAS components and
the search for new serum biomarkers.
Here, we describe the activity of five crucial angiotensin-
regulating peptidases (ACE, ACE2, aminopeptidase A (APA),
aminopeptidase N (APN), and neutral endopeptidase (NEP)
[1] in the serum of adult men and women. In our study, male
and female individuals were described as good models of
normal health and considered to be “control” subjects for
chronic diseases. All participants were between 41 and
70 years old (typically, this is the age of onset of several
cardiovascular and proliferative disorders and early stages of
neurodegenerative diseases [11–13]), did not have any
chronic pathology, and were not under any pharmacological
treatment. Using this cohort, we sought to detect sex
differences in RAS peptidase serum activity with aging.
Methods
Participants
Participants in this study comprised 118 healthy individuals
with no history of any cardiovascular, proliferative, or cen-
tral nervous system degenerative disease, ranging from 41–
70 years old (60 males; age 56.58 ± 6.47 years; 58 females;
age 54.47 ± 4.99 years). All participants underwent thor-
ough medical examination, and we excluded all those who
presented chronic pathologies involving drug treatment,
such as estrogen replacement therapy, hormonal contracep-
tives or testosterone, or any significant neurologic, systemic,
or psychiatric disorder that could cause cognitive impair-
ment, as well as any who were pregnant or breastfeeding.
All participants were informed of the extent of the study
and signed an informed consent document approved by the
Ethical and Scientific Committees (CEIC PGA-2).
Sample preparation
Blood samples (10 mL) were collected by venipuncture
into heparinized tubes after fasting overnight. Following
centrifugation (1500 rpm, for 10 min), serum samples
were separated and stored frozen at −80 °C until the
analysis of renin–angiotensin system enzyme activity.
Renin–angiotensin system-regulating enzyme activity
Enzyme activity in serum samples was measured by spectro-
fluorimetry in a microplate reader fluorometer FLUOstar
OPTIMA (BMG Labtech). Angiotensin-converting enzyme
(ACE/CD143: EC 3.4.11.1), angiotensin-converting enzyme 2
(ACE 2: EC 3.4.17.23), aminopeptidase A (APA/CD143: EC
3.4.11.7), aminopeptidase N (APN/CD13: EC 3.4.11.2), and
neutral endopeptidase (NEP/CD10: EC 3.4.24.11) activity
were measured. All samples were analyzed in triplicate and
incubated at 37 ° C with their respective fluorogenic sub-
strates in microplates for either 30 min (ACE, APA, APN,
NEP/CD10) or 2 h (ACE2). Blanks were also included. The
incubation times were based on preliminary assays to assess
the linearity of the reaction over time as well as protein con-
tent. When introduced into the fluorimeter, specific emission
and excitation filters for each substrate were selected. Each
well was assayed with 10 flashes and the signals obtained
were averaged. The value for the blank was discounted. The
enzyme activity was expressed as units of enzyme activity per
milliliter of serum (U/mL). One unit of activity is the amount
of enzyme required to release 1 pmol of fluorescent product
per minute. Specific inhibition assays for each substrate were
performed to ensure appropriate measurement (86% or more
inhibition accuracy was accepted).
ACE activity assay
Estimation of ACE activity was based on the fluorescence
of the product generated upon hydrolysis by the enzyme
of the substrate Abz-Gly-Phe(NO2) Pro (Bachem E2920).
Fifty microliters of serum samples and 250 μL of substrate
with 150 mM Tris-Hcl buffer, pH 8.3, plus 0.3 M NaCl
were placed in a microplate reader and incubated as previ-
ously described. Excitation was at 355 nm and emission at
410 nm. The inhibition assay for ACE activity was per-
formed with captopril (10 μM, Sigma).
ACE2 activity assay
The ACE2 activity assay was based on the fluorescence of
the product generated upon hydrolysis by the enzyme of the
substrate Abz-Ser-Pro-3-nitro-Tyr-OH (SPNPT; Bachem
E2920). Reactions were initiated by adding 70 μL of the
appropriate incubation mixture (substrate, 50 mM Tris-HCl
buffer, pH 7.5, 2 μg BSA) to 30 μL of sample. After incuba-
tion, the fluorescence intensity was measured with an excita-
tion filter at 355 nm and an emission filter at 410 nm. The
inhibition assay for ACE2 activity was performed using
DX600 (1 μM, Bachem).
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APA and APN/CD13 activity assay
APA and APN/CD13 activity were measured using APA-
β-naphthylamide as a substrate (Sigma N8381). Both were
dissolved in 50 mM phosphate buffer. In the case of APA
activity, 10 μL of serum were incubated with 190 μL of
the mixture and 2 μg BSA, DTT, and CaCl2 were added
to ensure that the reaction occurred. For APN activity,
not only 2 μg of BSA but also the specific AlaAP inhibitor
puromycin (40 μM) was added to discriminate between
the AlaAP and APN/CD13 forms of total alanine amino-
peptidase activity. Excitation was at 340 nm and emission
at 410 nm. APA inhibition assay was performed using
1,10-phenanthroline (1,2 mM, Sigma) and APN/CD13
using leuhistin (0,05 mM, Sigma).
NEP/CD10 activity assay
The NEP/CD10 assay was performed by incubating 30-
μL samples with 70 μL of a saturating concentration of
N-dansyl-D-Ala-Gly-pNO2-Phe-Gly (DAGNPG, Sigma
E39220). Captopril was added to discriminate between
NEP activity and ACE forms. Excitation was at 340 nm
and emission at 562 nm. NEP inhibition was performed
using DL-thiorphan (Sigma).
Statistical analyses
To compare sexes, the female and male groups were each
subdivided into two groups, separated by the median value of
the sample. All reported values represent the median of the
individual determination ± interquartile range (IQR). Statis-
tical analysis was performed using SPSS® Statistics version 21.
The Kolmogorov–Smirnov test was used to test the normal-
ity distribution of the data. A Mann–Whitney U test was per-
formed to detect differences between the sexes, as well as
between younger (<55 years) and older (≥55 years) partici-
pants when variables showed a non-normal distribution.
Linear regression models using systolic and diastolic
blood pressures as dependent variables and enzyme ac-
tivities as independent variables, as well as sex and age
as independent variables of influence, were applied. Add-
itionally, a linear regression analysis between age and
renin–angiotensin system-regulating enzyme activities in
women and men was performed.
Results
Descriptive parameters of 128 participants (all of them
meeting inclusion criteria) are provided in Table 1. Men
were found to have higher body mass indexes and higher
blood pressure than women, as well as a lower body fat
percentage. These differences were maintained among the
specific age groups when a breakpoint of 55 years was se-
lected to compare those less than or greater than 55 years
of age (Table 2). A lack of changes in these parameters
was observed in men when comparing the under 55 group
to those over 55 years and in women over 55, presented a
tendency toward higher systolic blood pressure (P = 0.078)
compared to women under 55 years (Table 3).
Table 1 Descriptive statistics of the study population
WOMEN MEN Mann–Whitney U
Median IQR N Median IQR N Z P value
Age (years) 54.97 6.34 58 55.76 10.18 60 −1.55 0.121
BMI (kg/m2) 23.45 4.15 58 25.65 3.83 60 −3.51 <0.001
Body fat (%) 30.70 11.95 58 20.61 10.53 60 −5.61 <0.001
SBP (mmHg) 120.5 21.5 58 130.1 21.5 60 −3.34 0.001
DBP (mmHg) 80 5.25 58 80 3.75 60 −2.57 0.010
Note: BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure
Table 2 Sex differences in BMI, body fat percentage, SBP, and DBP in younger (<55 years) and older (≥55 years) participants
WOMEN MEN Mann–Whitney U
Median IQR N Median IQR N Z P value
< 55 years BMI (kg/m2) 23.5 4.4 28 25.4 4.5 31 −2.336 0.020
Body fat (%) 30.1 14.9 28 20.2 10 31 −4.246 <0.001
SBP (mmHg) 120 13 28 130 19 31 −2.783 0.005
DBP (mmHg) 78.5 7 28 80 8 31 −0.005 0.047
> 55 years BMI (kg/m2) 23.35 3.8 30 26.2 3.9 29 −2.664 0.008
Body fat (%) 31.15 9.6 30 20.7 10.8 29 −3.735 0.000
SBP (mmHg) 127 21 30 135 23 29 −1.803 0.071
DBP (mmHg) 80 5 30 80 0 29 −1.683 0.092
Note: BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure
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ACE, ACE2, NEP, APN, and APA serum enzymatic ac-
tivities were measured in men and women (Table 4). Sig-
nificantly lower serum APA activity levels were observed
in men with respect to women; no changes were ob-
served for ACE, ACE2, NEP, or APN.
When we compared serum enzymatic activities separately
in younger and older participants (breakpoint 55 years)
(Table 5), significantly lower ACE and APA serum activity
levels were observed in men with respect to women, but
without changes in ACE2, NEP, or AP. However, in the case
of younger participants, significantly higher NEP serum en-
zymatic activity was observed in men than in women, but
without changes in ACE, ACE2, APN, or APA. In contrast,
in the case of older participants, significantly lower ACE
and APA serum activity was observed in men than in
women, but without changes in ACE2, NEP, or APN.
The effects of age, with a breakpoint of 55 years, on
ACE, ACE2, NEP, APN, and APA serum activity was mea-
sured in all the participants, as well as separately in men
and women (Table 6). Significantly lower ACE and a trend
toward lower APA (P = 0.063) serum enzymatic activity
was detected in older men, but without changes in ACE2,
NEP, or APN. In women, significantly higher ACE2 serum
activity was observed in older women, but with no
changes in ACE, NEP, APN, or APA. To evaluate the stat-
istical association between age and serum aminopeptidase
activities, linear regression models were applied separately
in women and men (Table 7). These analyses indicated a
positive association between ACE2 serum activity and age
in women. Accordingly, a linear regression model using
systolic and diastolic blood pressure as dependent vari-
ables and enzyme activities as independent variables, as
well as sex and age as independent variables of influence,
showed that age, sex, and ACE2 influence systolic blood
pressure, while only sex influences diastolic blood pres-
sure, across the continuum of age (Table 8).
Discussion
Our results revealed sex differences in RAS serum enzymatic
activities. Sex differences in soluble aminopeptidases, such as
APA, have been described by other authors [19]. Moreover, it
has been suggested that sex differences in blood pressure
could be due to the effects of sex hormones on some of these
peptidases, which are critical for the regulation of RAS [20].
In the present work, a critical range of age was selected for
the inclusion of participants, all of whom were healthy
middle-aged individuals, thus leading to a methodological
improvement with respect to previous studies on this topic.
It has been proposed that sex differences in the regulation
of arterial pressure by RAS could be due in part to a decrease
in ACE serum activity in males, contrasting with a predomin-
ant ACE2 activity in females that could be lost in the post-
menopausal period [16]. Sex differences in the incidence and
evolution of cardiovascular disease and hypertension are also
Table 3 Effects of age (breakpoint >55 years) on BMI, body fat percentage, SBP, and DBP in all participants
< 55 years > 55 years U Mann–Whitney
Median IQR N Median IQR N Z P value
WOMEN BMI (kg/m2) 23.5 4.4 28 23.35 3.8 30 −0.537 0.591
Body fat (%) 30.1 14.9 28 31.15 9.6 30 −0.265 0.791
SBP (mmHg) 120 13 28 127 21 30 −1765 0.078
DBP (mmHg) 78.5 7 28 80 5 30 −0.459 0.646
MEN BMI (kg/m2) 25.4 4.5 31 26.2 3.9 29 −0.059 0.953
Body fat (%) 20.2 10 31 20.7 10.8 29 −0.792 0.429
SBP (mmHg) 130 19 31 135 23 29 −1297 0.195
DBP (mmHg) 80 8 31 80 0 29 −0.182 0.856
Note: BMI Body mass index, SBP Systolic blood pressure, DBP diastolic blood pressure
Table 4 Renin–angiotensin system-regulating enzyme activities and sex differences
TOTAL WOMEN MEN Mann–Whitney U
Median IQR N Median IQR N Median IQR N Z P value
ACE 783.3 253.31 118 820.3 253.32 58 771.3 254.27 60 −1.281 0.2
ACE2 64.33 21.59 118 64.66 18.49 58 63.12 27.14 60 −0.350 0.726
NEP 15702 1724.59 118 15594 1272.12 58 15846 1974.44 60 −1.066 0.286
APN 10260 5417.84 118 10238 599.2 58 10436 4937.59 60 −0.711 0.477
APA 4143 1296.75 118 4345 1225.79 58 3946 991.35 60 −2.153 0.031
Note: ACE angiotensin-converting enzyme, ACE2 angiotensin-converting enzyme-2, NEP neutral endopeptidase, APN aminopeptidase N, APA aminopeptidase A
Values are medians of peptidase activity recorded as pmol of units of peptidase (UP) per milliliter of serum
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suggested to be due to the differential effects of sex steroids
on critical components of RAS, which could possibly explain
sex differences in blood pressure levels [21].
To detect specific physiological sex differences in the
serum activities of RAS peptidases, we selected participants
ranging from 41 to 70 years old, representing a period of
time in which the onset of several cardiovascular and prolif-
erative disorders and early stages of neurodegenerative
diseases is most prevalent [11–13], who did not have any
chronic pathology, and were not under any pharmaco-
logical treatment. Consequently, this sample was intended
to constitute a specific ideal model, to avoid bias caused by
concomitant pathologies and/or medications.
Estrogen decrease, whereas testosterone increases, ACE
activity, and consequently Ang II levels [20]. Accordingly,
in our study, men aged ≥55 years showed a significantly
lower ACE activity with respect to women. Further, among
men, a significant reduction in ACE activity was observed
in older participants (>55 years), with respect to younger
ones (<55 years). These results suggest a greater influence
on ACE activity by testosterone, compared to estrogens.
Post-menopausal changes in estrogen levels are well
known [22], as a consequence of the physiological decline
in ovarian follicle numbers [23], leading to sleep and body
temperature disturbances in older women [24]. Although
andropausia has been described as a controversial concept
[25], it has been suggested that androgen deficiency in
older men has been overlooked in clinical settings [26]. In
2006, the Massachusetts Male Aging Study (MMAS) de-
scribed a reduction in testosterone levels in 21% of men
aged 55–59 years, 26% of those aged 60–69 years, and
31% of those aged 70–86 years [27]. In fact, late-onset
hypogonadism (age-related testosterone deficiency) has
been recently recognized as a clinical syndrome associated
with low testosterone levels and alteration of health status
[28, 29], and the possibility that subclinical hypogonadism
in andropausal men could be a physiologic response of
the hypothalamus has been proposed [30]. The breakpoint
Table 5 Sex differences in ACE, ACE2, NEP, APN, and APA serum activities in younger (<55 years) and older (≥ 55 years) participants
WOMEN MEN Mann–Whitney U
Median IQR N Median IQR N Z P value
< 55 years ACE 820.3 249.77 28 841.4 281.02 31 −0.728 0.467
ACE2 61.71 16.69 28 59.75 23.57 31 −0.032 0.975
NEP 15474 1187.55 28 16203 2030.32 31 −2.017 0.044
APN 9931 5046.74 28 11517 6916.75 31 −1.653 0.098
APA 4304 1225.79 28 4281 1633.4 31 −0.121 0.903
> 55 years ACE 815.9 272.13 30 744.4 201.43 29 −2.292 0.022
ACE2 71.11 16.22 30 70,05 30.92 29 −0.378 0.706
NEP 15703 1812.15 30 15344 1668.93 29 −0.562 0.574
APN 10238 6688.67 30 9973 4001.23 29 −0.577 0.564
APA 4361 1240.15 30 3820 623.97 29 −2.763 0.006
Note: ACE angiotensin-converting enzyme, ACE2 angiotensin-converting enzyme-2, NEP neutral endopeptidase, APN aminopeptidase N, APA aminopeptidase A
Table 6 Effects of age (breakpoint >55 years) on ACE, ACE2, NEP, APN, and APA serum activities in women and men
<55 years ≥ 55 years Mann–Whitney U
Median IQR N Median IQR N Z P value
WOMEN ACE 820.3 249.77 28 815.9 272.13 30 −0.731 0.465
ACE2 61.71 16.69 28 71.11 16.22 30 −2.169 0.030
NEP 15474 1187.55 28 15703 1812.15 30 −0.965 0.335
APN 9931 5046.74 28 10238 6688.67 30 −0.747 0.455
APA 4304 1225.79 28 4361 1240.15 30 −0.327 0.744
MEN ACE 841.4 281.02 31 744.4 201.43 29 −1.960 0.049
ACE2 59.75 23.57 31 70.05 30.92 29 −1.007 0.313
NEP 16203 2030.32 31 15344 1668.93 29 −1.013 0.311
APN 11517 6916.75 31 9973 4001.23 29 −1.620 0.105
APA 4281 1633.4 31 3820 623.97 29 −1.856 0.063
Note: ACE angiotensin-converting enzyme, ACE2 angiotensin-converting enzyme-2, NEP neutral endopeptidase, APN aminopeptidase N, APA aminopeptidase A
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of 55 years selected for comparisons between groups of
age in our study is relevant to these findings.
Pre-menopausal women have lower blood pressure with
respect to post-menopausal women [31] and pre-
andropausal men [32], indicating that a difference in car-
diovascular risk could be mediated by RAS. In fact, andro-
gens can stimulate RAS [33], and the sexually dimorphic
pattern of hypertension in the spontaneously hypertensive
rat is androgen-dependent, rather than estrogen-dependent
[34]. Accordingly, serum peptidases, such as ACE, ACE2,
NEP, APN, and APA, which are important elements of the
RAS, were studied here because dysregulation of these
enzymes has been associated with hypertension and cardio-
vascular risk [35]. Our results revealed sexual differences in
these activities, with a different pattern in pre- and post-
andropausal/post-menopausal subjects.
Sex differences in APA activity were observed in the se-
lected subjects. More precisely, a significantly lower serum
activity of this enzyme was found in men than in women.
These results suggest lower production of angiotensin III in
men, which exerts an important physiological regulatory
action on cerebral circulation [36]. However, a different pat-
tern of sexual differences was observed in participants
≥55 years of age. In this group, significantly lower APA and
ACE serum activities were observed in men compared to
women. Considering that angiotensin III promotes in-
creased blood pressure when injected intracerebroventricu-
larly [37], and taking into account that it has been reported
that inhibitors of APA, the enzyme that produces angioten-
sin III, can act as antihypertensive drugs [38, 39]; these re-
sults could help explain the smaller changes in blood
pressure usually observed in post-andropausal men, with
respect to that observed in post-menopausal women.
The reduction in APA activity may be linked to a de-
crease in the production of angiotensin III, leading to a
reduction in cerebral vasoconstriction. This could pre-
vent the elevation of cerebral blood pressure, thus con-
tributing to the decrease in cerebrovascular risk found
in post-andropausal men compared to post-menopausal
women. However, in participants <55 years old, although
significantly higher NEP and APN serum activities were
observed, a lack of changes in ACE, ACE2, and APA
serum activities was observed in men, with respect to
women. Notably, reduced APA could be linked to higher
levels of angiotensin II, thus tending to increase blood
pressure. Further, elevated NEP in younger men could
increase angiotensin 1-7, reducing this parameter.
With respect to aging, these serum enzymatic activities
presented sex differences in the activity patterns when it
was observed between younger (<55 years) and older
(≥55 years) participants. Thus, higher ACE2 activity was
found in older women, whereas lower ACE and APA
activities were observed in older men. Due to the fact that
ACE2 activity can increase production of angiotensin 1-7,
which leads to vasodilatatory, antiproliferative, and
antifibrotic effects [40], and considering that antithrom-
botic effects have been recently proposed for the ACE2-
angiotensin (1-7)-Mas receptor axis [41], the increase in
ACE2 activity in the post-menopausal period in women
could lead to a differential cardiovascular risk in men and
women [42].
Table 7 Linear regression anaysis between age and
renin–angiotensin system-regulating enzyme activities in
women and men
B (95% CI) β R2 P value
ACE Women 5.979 (−5.408, 17.365) 0.139 0.019 0.297
Men −6.139 (−14.206, 1.927) −0.196 0.038 0.133
ACE2 Women 0.959 (0.323, 1.595) 0.38 0.145 0.004
Men 0.664 (−0.193, 1.521) 0.205 0.042 0.126
NEP Women 14.87 (−48.08, 77.82) 0.063 0.004 0.638
Men −52.80 (−105.2, −0.402) −0.256 0.066 0.048
APN Women 162.9 (−68.22, 394.1) 0.185 0.034 0.163
Men −116.4 (−266.7, 33.78) −0.2 0.040 0.126
APA Women 51.75 (−16.21, 119.7) 0.2 0.040 0.133
Men −29.23 (−72.52, 14.06) −0.175 0.031 0.182
Note: ACE angiotensin-converting enzyme, ACE2 angiotensin-converting
enzyme-2, NEP neutral endopeptidase, APN aminopeptidase N, APA
aminopeptidase A
Table 8 Linear regression models including systolic blood pressure and diastolic blood pressure as dependent variables and
enzyme activities as independent variables, as well as sex and age as independent variables of influence
Dependent variables Predictors B (95% CI) β R2 Adjusted R2 SEE P value
SBP Model 0.478 0.228 15.263 <0.001
Age (years) 110.54 (47.06, 174.03) 0.304 0.001
Sex −7.22 (−13.02,−1.43) −0.221 0.015
ACE2 27.99 (3.19, 82.78) 0.194 0.027
Constant −101.9 (−212.9, 9.22) 0.071
DBP Model 0.225 0.051 6.685 <0.001
Sex −3.06 (−5.55,−0.57) −0.221 0.015
Constant 84.71 (80.78, 88.64) <0.001
Note: SBP systolic blood pressure, DBP diastolic blood pressure, ACE2 angiotensin-converting enzyme-2
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Although post-menopausal women are known to have an
increased cardiovascular risk, this fact does not necessary
contradict the beneficial cardiovascular effects of the in-
crease in ACE2 activity in older women. Thus, it cannot be
discarded that the ACE2-ang1-7-Mas axis could counter-
balance negative cardiovascular effects of other age-related
mechanisms. Further studies are needed to detect angioten-
sin peptide changes induced by aging in both sexes.
A limitation of the study could be that we lack data
regarding alcohol consumption, cigarette smoking status,
or physical activity habits, additional information that
could influence RAS activity. However, we must
emphasize that in meeting our inclusion criteria, the
participants did not have any chronic pathology and
were not under any pharmacological treatment, making
this a reasonably good sample for this study.
Conclusions
These results highlight sex differences in the aging pattern
of renin–angiotensin system serum peptidases, suggesting
a differential effect of aging in men, especially with respect
to the breakpoint of andropausia, on the critical serum
enzymatic activities of the RAS, which could correlate
with sexual differences in cardiovascular risk.
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